# Lifeward Ltd. (LFWD) — capital_raise/private_placement [pending]
Source: SEC API (secapi.ai) · situation sit_afbbdcb0e1335b6911b6 · retrieved 2026-08-11T15:53:10.914Z

## Overview
Lifeward Ltd. is a medical device company that designs, develops, and commercializes robotic exoskeleton devices (ReWalk Personal and ReWalk Rehabilitation) for individuals with spinal cord injury, enabling them to stand and walk again in home and community settings.

On January 12, 2026, Lifeward Ltd. entered into a Share Purchase Agreement with Oramed Pharmaceuticals Inc. and Oratech Pharma, Inc. to acquire 100% of Oratech's outstanding equity interests. As consideration, Lifeward will issue to Oramed approximately 131,297,754 Ordinary Shares (based on outstanding shares as of January 20, 2026) and pre-funded warrants equal to 49.99% of the Company's fully diluted equity capitalization at closing, with the number of Ordinary Shares not to exceed 45.00% of outstanding shares immediately after closing. Additionally, Lifeward will issue transaction warrants to Oramed based on Oratech's net cash at closing (at $0.45 exercise price) and pay quarterly revenue sharing payments equal to 4% of ReWalk Product net revenue for up to 10 years or until Oramed receives a maximum aggregate amount or the Company's market capitalization reaches $200 million, whichever is earliest. The transaction is subject to shareholder approval and customary closing conditions, including Nasdaq listing approval and Oratech maintaining at least $7 million in net cash at closing.

## Terms
- Counterparty: Oramed Pharmaceuticals Inc. · Consideration: stock · Stake: 49.99% · Price/share: $5.4

## Key dates
- Announced 2026-07-07 · Record 2026-01-20 · Vote 2026-03-12 · Expected close 2026-07-06

## Timeline
- 2026-02-09 · DEFM14A (0001178913-26-000362): DEFM14A - Lifeward Ltd. — *Lifeward Ltd. is a medical device company that designs, develops, and commercializes robotic exoskeleton devices (ReWalk Personal and ReWalk Rehabilitation) for individuals with spinal cord injury, enabling them to stand and walk again in home and community settings.* On January 12, 2026, Lifeward Ltd. entered into a Share Purchase Agreement with Oramed Pharmaceuticals Inc. and Oratech Pharma, Inc. to acquire 100% of Oratech's outstanding equity interests. As consideration, Lifeward will issue to Oramed approximately 131,297,754 Ordinary Shares (based on outstanding shares as of January 20, 2026) and pre-funded warrants equal to 49.99% of the Company's fully diluted equity capitalization at closing, with the number of Ordinary Shares not to exceed 45.00% of outstanding shares immediately after closing. Additionally, Lifeward will issue transaction warrants to Oramed based on Oratech's net cash at closing (at $0.45 exercise price) and pay quarterly revenue sharing payments equal to 4% of ReWalk Product net revenue for up to 10 years or until Oramed receives a maximum aggregate amount or the Company's market capitalization reaches $200 million, whichever is earliest. The transaction is subject to shareholder approval and customary closing conditions, including Nasdaq listing approval and Oratech maintaining at least $7 million in net cash at closing.
  https://www.sec.gov/Archives/edgar/data/1607962/0001178913-26-000362.txt
- 2026-07-07 · 8-K (0001178913-26-003429): Lifeward issues $11.16M convertible notes, warrants; $5.58M closed July 6, second tranche conditional — *Lifeward Ltd. (formerly ReWalk Robotics) develops exoskeleton and robotic mobility solutions for individuals with spinal cord injuries and other mobility impairments.* On June 30, 2026, Lifeward Ltd. entered into a Securities Purchase Agreement with certain investors and Oramed Pharmaceuticals Inc. (as collateral agent) to issue senior secured convertible notes and accompanying warrants. The transaction closed on July 6, 2026, with the Company issuing $5,580,000 in aggregate principal amount of Initial Notes convertible into Ordinary Shares at $5.40 per share, plus Initial Warrants exercisable at $5.40 per share. The Company also agreed to issue an additional $5,580,000 in Second Notes and Second Warrants, subject to customary closing conditions and either (i) a 150% increase in ReWalk Unit Sales measured in U.S. dollars relative to the trailing twelve-month period preceding the Additional Closing Date, or (ii) the closing price of the Company's Ordinary Shares equaling or exceeding $13.80 per share on each Trading Day during the ten consecutive Trading Days immediately prior to the Additional Closing Date. The Notes mature three years from issuance, accrue interest at 8.0% per annum (increasing to 15.0% upon default), and are payable semi-annually on June 30 and December 31, commencing December 31, 2026. The Warrants are exercisable immediately and expire five years after issuance, exercisable for up to 100% of the Ordinary Shares that each Note is convertible into as of the issuance date.
  https://www.sec.gov/Archives/edgar/data/1607962/0001178913-26-003429.txt

## Citations
- 0001178913-26-000362 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000117891326000362
- 0001178913-26-003429 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000117891326003429